Nektar Therapeutics

NKTR
Real-time BATS EXCHANGE - 07/23 01:55:57 pm
32.155USD
-0.46%
Prev.32.3400
Open32.3900
High32.3900
Low31.9100
Volume908 005
Financials
Sales 2019 111 M
EBIT 2019 -533 M
Net income 2019 -538 M
Debt 2019 181 M
Yield 2019 -
P/E ratio 2019 -10,5x
P/E ratio 2020 -12,3x
EV / Sales2019 52,3x
EV / Sales2020 25,9x
Capitalization 5 637 M
Company
Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows:
- revenues from licensing and collaboration agreements (91.9%);
- product sales (4.6%);
- royalties...
Sector :
Biotechnology & Medical Research - NEC
Calendar :
2019-08-05 Earnings Release
Trading Rating :
Investor Rating :
Latest news
07/09Drugmakers Rise After Trump Pricing Rule Is Blocked
DJ
06/14NEKTAR THERAPEUTICS : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/13NEKTAR THERAPEUTICS : First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology
PR
06/11NEKTAR THERAPEUTICS : to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019)
PR
05/27NEKTAR THERAPEUTICS : COO Sells $127,895.49 in Stock
AQ
05/25TROVAGENE : Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD in Models of Colorectal Cancer
AQ
05/25NEKTAR THERAPEUTICS : unveils Inheris Biopharma, its new CNS-focused offshoot
AQ
05/25NEKTAR THERAPEUTICS : New Biopharmaceutical Company Launched with Focus on Pain Medication
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishBearishNeutral
Resistance34,137,666,5
Spread/Res.-5,7%-15%-52%
Spread/Supp.0,44%3,6%4,9%
Support32,031,030,6